BIOVENTUS INCORPORATED (BVS)

JPMorgan started BWX Technologies at overweight, citing Navy contracts and a nuclear power story the market is missing. Here is the case and the risks.

Shares of Bravura Solutions Ltd (ASX:BVS) were trading at $2.52 at the time of writing on 30 July 2026, gaining 0.40% for the session, as ASX technology stocks traded against a backdrop of a resilient broader local market and a weak overnight lead from Wall Street.

Boston Scientific underperformed the broader market, though analysts remain optimistic, citing strong earnings execution, innovation, and meaningful upside from current levels.

Earnings call transcript: BAE Systems lifts 2026 outlook as stock falls after hours, H1 2026

Wall Street expects a year-over-year ... Bioventus (BVS) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the ...